ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Other
ABL Bio Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other
-₩55.4m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other
₩628.1B
|
CAGR 3-Years
88%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Other
-₩60.8m
|
CAGR 3-Years
28%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Other
-₩23m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Other
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Other?
Other
-55.4m
KRW
Based on the financial report for Sep 30, 2025, ABL Bio Inc's Other amounts to -55.4m KRW.
What is ABL Bio Inc's Other growth rate?
Other CAGR 5Y
58%
Over the last year, the Other growth was 97%. The average annual Other growth rates for ABL Bio Inc have been -65% over the past three years , 58% over the past five years .
